Granted Patent
B2
US 12,595,513 · App. 16/799,797 · Granted Apr 7, 2026
Methods and materials for assessing loss of heterozygosity
Inventors:
Victor Abkevich (Salt Lake City, UT); Alexander Gutin (Salt Lake City, UT); Kirsten Timms (Salt Lake City, UT); Jerry Lanchbury (Salt Lake City, UT)
View Patent ↗
Loading inventors, assignments & file history…
Abstract
This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of a loss of heterozygosity (LOH) signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an LOH signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.
Claims (29)
1 . A method, comprising:
assaying a sample of DNA extracted from a cancer cell to genotype a plurality of single nucleotide polymorphism (SNP) loci in at least one pair of human chromosomes other than a human X/Y chromosome pair of the cancer cell by:
(i) enriching the sample for test DNA molecules each comprising at least one locus from the plurality of SNP loci using capture probes, thereby obtaining an enriched sample; and
(ii) sequencing the test DNA molecules to detect either a homozygous genotype or heterozygous genotype at SNP loci spaced about 25 kb to about 100 kb apart on one or more chromosome pairs other than a human X/Y sex chromosome pair; and
wherein the test DNA molecules comprise a loss of heterozygosity (LOH) Region, wherein each LOH Region is characterized by loss of heterozygosity with a length of about 1.5 or more megabases but shorter than the length of the whole chromosome containing the LOH Region.
2 . The method of claim 1 , wherein the plurality of SNP loci are present on at least 10 pairs of human chromosomes.
3 . The method of claim 1 , wherein the plurality of SNP loci are present on at least 21 pairs of human chromosomes.
4 . The method of claim 1 , wherein each LOH Region is equal to or longer than 5 megabases.
5 . The method of claim 1 , wherein each LOH Region is equal to or longer than 15 megabases.
6 . A method, comprising:
assaying a cancer cell sample obtained from a breast or ovarian cancer patient to detect DNA comprising a loss of heterozygosity (LOH) Region in at least one pair of human chromosomes other than the human X/Y sex chromosome pair, wherein
assaying comprises genotyping a plurality of single nucleotide polymorphism (SNP) loci by
(i) enriching the sample for test DNA molecules each comprising at least one locus from the plurality of SNP loci using capture probes, thereby obtaining an enriched sample, and
(ii) sequencing the test DNA molecules to determine whether SNP loci spaced about 25 kb to about 100 kb apart on one or more chromosome pairs other than a human X/Y sex chromosome pair are homozygous or heterozygous, and
wherein the test DNA molecules comprise a LOH Region, wherein the LOH Region is defined as a genomic region wherein all SNP loci genotyped are homozygous, wherein such genomic region is equal to or longer than a first length but shorter than the length of the whole chromosome containing the genomic region, and wherein the first length is at least 1.5 megabases.
7 . The method of claim 6 , wherein the plurality of SNP loci are present on at least 10 pairs of human chromosomes.
8 . The method of claim 6 , wherein the length of the first length is at least 5 megabases.
9 . The method of claim 6 , wherein the length of the first length is at least 15 megabases.
10 . The method of claim 1 , wherein the plurality of SNP loci comprises at least 1,000 SNP loci.
11 . The method of claim 1 , wherein the plurality of SNP loci comprises at least 10,000 SNP loci.
12 . The method of claim 1 , wherein the plurality of SNP loci comprises at least 25,000 SNP loci.
13 . The method of claim 1 , wherein the plurality of SNP loci comprises at least 50,000 SNP loci.
14 . The method of claim 1 , wherein the cancer cell is a breast cancer cell or an ovarian cancer cell.
15 . The method of claim 6 , wherein the plurality of SNP loci comprises at least 1,000 SNP loci.
16 . The method of claim 6 , wherein the plurality of SNP loci comprises at least 10,000 SNP loci.
17 . The method of claim 6 , wherein the plurality of SNP loci comprises at least 25,000 SNP loci.
18 . The method of claim 6 , wherein the plurality of SNP loci comprises at least 50,000 SNP loci.
19 . The method of claim 1 , wherein the plurality of SNP loci are present on at least 5 pairs of human chromosomes.
20 . The method of claim 6 , wherein the plurality of SNP loci are present on at least 5 pairs of human chromosomes.
Assignments (5)
SECURITY INTEREST
Recorded Aug 1, 2025
From: MYRIAD GENETICS, INC.; MYRIAD GENETIC LABORATORIES, INC.; MYRIAD WOMEN’S HEALTH, INC.; ASSUREX HEALTH, INC.; GATEWAY GENOMICS, LLC
To: ORBIMED ROYALTY & CREDIT OPPORTUNITIES IV, LP, AS ADMINISTRATIVE AGENT FOR SECURED PARTIES
Reel/Frame 072309/0932 →
RELEASE OF SECURITY INTEREST IN PATENTS PREVIOUSLY RECORDED AT REEL/FRAME (064235/0032)
Recorded Aug 1, 2025
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: MYRIAD GENETICS, INC.; MYRIAD WOMEN’S HEALTH, INC.; GATEWAY GENOMICS, LLC; ASSUREX HEALTH, INC.
Reel/Frame 072331/0215 →
PATENT SECURITY AGREEMENT
Recorded Jul 7, 2023
From: MYRIAD GENETICS, INC.; MYRIAD WOMEN'S HEALTH, INC.; GATEWAY GENOMICS, LLC; ASSUREX HEALTH, INC.
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 064235/0032 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 26, 2023
From: MYRIAD GENETICS, INC.
To: MYRIAD GENETICS, INC.; THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
Reel/Frame 063778/0231 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Oct 18, 2021
From: ABKEVICH, VICTOR; GUTIN, ALEXANDER; TIMMS, KIRSTEN; LANCHBURY, JERRY
To: MYRIAD GENETICS, INC.
Reel/Frame 057818/0063 →
Continuity (6)
Continuation
PCTUS2012071380
· Dec 21, 2012
Provisional Application
61654402
· Jun 1, 2012
Provisional Application
61578713
· Dec 21, 2011
References Cited (310)
US 3590028A
· Arcamone et al.
· 1971
[cited by applicant]
US 3892790A
· Tobe et al.
· 1975
[cited by applicant]
US 3904663A
· Tobe et al.
· 1975
[cited by applicant]
US 4138480A
· Gosalvez
· 1979
[cited by applicant]
US 4946954A
· Talebian et al.
· 1990
[cited by applicant]
US 4950738A
· King et al.
· 1990
[cited by applicant]
US 4996337A
· Bitha et al.
· 1991
[cited by applicant]
US 5091521A
· Kolar et al.
· 1992
[cited by applicant]
US 5177075A
· Suto et al.
· 1993
[cited by applicant]
US 5295944A
· Teicher et al.
· 1994
[cited by applicant]
US 5434256A
· Khokhar et al.
· 1995
[cited by applicant]
US 5445934A
· Fodor et al.
· 1995
[cited by applicant]
US 5510270A
· Fodor et al.
· 1996
[cited by applicant]
US 5527905A
· Sugimura et al.
· 1996
[cited by applicant]
US 5539083A
· Cook et al.
· 1996
[cited by applicant]
US 5556752A
· Lockhart et al.
· 1996
[cited by applicant]
US 5578832A
· Trulson et al.
· 1996
[cited by applicant]
US 5633016A
· Johnson
· 1997
[cited by applicant]
US 5633243A
· Sugimura et al.
· 1997
[cited by applicant]
US 5744305A
· Fodor et al.
· 1998
[cited by applicant]
US 5858662A
· Keating
· 1999
[cited by applicant]
US RE36397E
· Zhang et al.
· 1999
[cited by applicant]
US 6040138A
· Lockhart et al.
· 2000
[cited by applicant]
US 6087340A
· Gatti et al.
· 2000
[cited by applicant]
US 6210891B1
· Nyren et al.
· 2001
[cited by applicant]
US 6214821B1
· Daoud
· 2001
[cited by applicant]
US 6258568B1
· Nyren
· 2001
[cited by applicant]
US 6274320B1
· Rothberg et al.
· 2001
[cited by applicant]
US 6403563B1
· Geroni et al.
· 2002
[cited by applicant]
US 6455258B2
· Bastian et al.
· 2002
[cited by applicant]
US 6465177B1
· Hoon
· 2002
[cited by applicant]
US 6534293B1
· Barany et al.
· 2003
[cited by applicant]
US 7351701B2
· Helleday et al.
· 2008
[cited by applicant]
US 7485707B2
· Matvienko et al.
· 2009
[cited by applicant]
US 7732491B2
· Sherman et al.
· 2010
[cited by applicant]
US 7754684B2
· Stewart et al.
· 2010
[cited by applicant]
US 7759488B2
· Xiao et al.
· 2010
[cited by applicant]
US 7759510B2
· Kay et al.
· 2010
[cited by applicant]
US 7858331B2
· D'Andrea et al.
· 2010
[cited by applicant]
US 7868040B2
· Wilson et al.
· 2011
[cited by applicant]
US 7915280B2
· Ferraris et al.
· 2011
[cited by applicant]
US 9279156B2
· Gutin et al.
· 2016
[cited by applicant]
US 9388472B2
· Abkevich
· 2016
[cited by applicant]
US 9574229B2
· Gutin et al.
· 2017
[cited by applicant]
US 20030049613A1
· Perucho et al.
· 2003
[cited by applicant]
US 20050064476A1
· Huang
· 2005
[cited by applicant]
US 20050112604A1
· Fujimoto et al.
· 2005
[cited by applicant]
US 20060088870A1
· Finkelstein et al.
· 2006
[cited by applicant]
US 20060094056A1
· Chappell
· 2006
[cited by applicant]
US 20070004621A1
· Shridhar et al.
· 2007
[cited by applicant]
US 20070070349A1
· Harris et al.
· 2007
[cited by applicant]
US 20080108057A1
· Griffith et al.
· 2008
[cited by applicant]
US 20080262062A1
· Ossovskaya et al.
· 2008
[cited by applicant]
US 20090081237A1
· D'Andrea et al.
· 2009
[cited by applicant]
US 20090246789A1
· Buckhaults et al.
· 2009
[cited by applicant]
US 20100145894A1
· Semizarov et al.
· 2010
[cited by applicant]
US 20100159466A1
· Eng
· 2010
[cited by applicant]
US 20120015050A1
· Abkevich et al.
· 2012
[cited by applicant]
US 20130281312A1
· Richardson et al.
· 2013
[cited by applicant]
US 20140363521A1
· Abkevich et al.
· 2014
[cited by applicant]
US 20150080260A1
· Abkevich et al.
· 2015
[cited by applicant]
US 20230117133A1
· Abkevich
· 2023
[cited by examiner]
CN 102083314
· 2011
[cited by applicant]
EP 0430402A2
· 1991
[cited by applicant]
EP 1260520A2
· 2002
[cited by applicant]
EP 2794907
· 2014
[cited by applicant]
EP 2981624A2
· 2016
[cited by applicant]
KR 100925337B1
· 2009
[cited by applicant]
WO WO9520952
· 1995
[cited by applicant]
WO WO9841531
· 1998
[cited by applicant]
WO WO9954498
· 1999
[cited by applicant]
WO WO0024933
· 2000
[cited by applicant]
WO WO03074723A2
· 2003
[cited by applicant]
WO WO2004042032A2
· 2004
[cited by applicant]
WO WO2004075833A2
· 2004
[cited by applicant]
WO WO2006098978A1
· 2006
[cited by applicant]
WO WO2006110855A2
· 2006
[cited by applicant]
WO WO2006116341A1
· 2006
[cited by applicant]
WO WO2006128195A2
· 2006
[cited by applicant]
WO WO2007035893A2
· 2007
[cited by applicant]
WO WO2009033178A1
· 2009
[cited by applicant]
WO WO2009073869A1
· 2009
[cited by applicant]
WO WO2009148528A2
· 2009
[cited by applicant]
WO WO2010051318A2
· 2010
[cited by applicant]
WO WO2011048495A1
· 2011
[cited by applicant]
WO WO2011106541A2
· 2011
[cited by applicant]
WO WO2011160063A2
· 2011
[cited by applicant]
WO WO2012019000A2
· 2012
[cited by applicant]
WO WO2012027224A1
· 2012
[cited by applicant]
WO WO2012092426A1
· 2012
[cited by applicant]
WO WO2013096843A1
· 2013
[cited by applicant]
WO WO2013130347A1
· 2013
[cited by applicant]
WO WO2013182645A1
· 2013
[cited by applicant]
WO WO2014165785A2
· 2014
[cited by applicant]
WO WO2015086473A1
· 2015
[cited by applicant]
WO WO2015108986A1
· 2015
[cited by applicant]
Walsh, C.S. et al. Clin. Cancer Res. 14(23):7645-7651 (Dec. 2008). (Year: 2008).
[cited by examiner]
Walsh, C.S. et al, Clin. Cancer Res. 14(23):7645, Supplemental Figure S1A. (Year: 2008).
[cited by examiner]
Walsh, C.S. et al, Clin. Cancer Res. 14(23):7645, Supplemental Figure S1B. (Year: 2008).
[cited by examiner]
Walsh, C.S. et al, Clin. Cancer Res. 14(23):7645, Supplemental Figure S1C. (Year: 2008).
[cited by examiner]
Tuna, M. et al. PLoS ONE 5(11):e15094. Nov. 2010. (Year: 2010).
[cited by examiner]
Ragoussis, J. Annu. Rev. Genomics Hum. Genet. 10:117-33. (Year: 2009).
[cited by examiner]
Mamanova, L. et al. Nature Methods 7(2):111. Feb. 2010. (Year: 2010).
[cited by examiner]
Zhang et al. (J. Oral Pathol Med., 2001, pp. 513-520) (Year:2001).
[cited by applicant]
Mora, et al., “Evolving significance of prognostic markerse associated with new treatment strategies in neuroblastoma”, Cancer Letters; 197 (2003) 119-124.
[cited by applicant]
Tutt, A., et al., “Mutation in Brca2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences”, EMBO, vol. 20, No. 17, Jan. 1, 2001 (Jan. 1, 2001), pp. 4704-4716.
[cited by applicant]
Affymetric Data Sheet “Gene-Chip Human Mapping 100K Set”; published 2005.
[cited by applicant]
De Waal et al., “Secondary Ovarian Malignancies: Frequency, Origin, and Characteristics”, Int J Gynecol Cancer, Oct. 2009;19(7):1160-5. doi: 10.1111/IGC.0b013e3181b33cce.
[cited by applicant]
Jelovac, D. and Armstrong, D.K., “Recent Progress in the Diagnosis and Treatment of Ovarian Cancer”, CA Cancer J Clin, 61/3, pp. 183-203, https://doi.org/10.3322/caac.20113, Apr. 26, 2011 (Apr. 26, 2011).
[cited by applicant]
Lehmann et al., “Computer Methods and Programs in Biomedicine”, 1996, vol. 50, p. 209-230, 1996.
[cited by applicant]
Li et al., “Single nucleotide polymorphism-based genome-wide chromosome copy change, loss of heterozygosity, and aneuploidy in Barrett's esophagus neoplastic progression”, Cancer Prev Res, Nov. 2008;1(6):413-23. doi: 10…
[cited by applicant]
Rhiem et al., “Sporadic Breast Carcinomas with Somatic BRCA1 Gene Deletions Share Genotype/Phenotype Features with Familial Breast Carcinomas”, Anticancer Res., Sep. 2010;30(9):3445-9.
[cited by applicant]
Tutt et al., “Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial”, Lancet, Jul. 24, 2010;376(9737):235-44. doi: 10.1016/S01…
[cited by applicant]
Abkevich et al., “Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer”, British Journal of Cancer, vol. 107, No. 10, Oct. 9, 2012, pp. 1776-1782.
[cited by applicant]
Abkevich et al., “Supplemental Material: Table S1: Validation of copy number determinations by Real Time PCR SNP ID Adjacent Gene Sample Copy Number by Real-Time PCR Copy Number by CCNT SNP A”,-1712744 CDKN2A HF505 0.01…
[cited by applicant]
Al-Mulla et al., “Metastatic recurrence of early-stage colorectal cancer is linked to loss of heterozygosity on hromosomes 4 and 14q” Journal of Clinical Pathology, 2006, vol. 59, No. 6, pp. 624-630.
[cited by applicant]
Anonymous: “Myriad's HRD Test Significantly Predicts Response to Cisplatin Treatment in Patients with Triple Negative Breast Cancer in Second Research Study”, Myriad, Dec. 2013.
[cited by applicant]
Argos et al., “Genomewide scan for loss of heterozygosity and chromosomal amplification in breast carcinoma using single-nucleotide polymorphism arrays”, Cancer Genetics and Cytogenetics, vol. 182, No. 2, Apr. 15, 2008,…
[cited by applicant]
Arlt et al., “BRCA1 is required for common-fragile-site stability via its g2/m checkpoint function,” Molecular and Cellular Biology, Aug. 2004, vol. 24, No. 15, pp. 6701-6709.
[cited by applicant]
Ashworth, “A synthetic lethal therapeutic approach: poly(adp) ribose polymerase inhibitors for the treatment of cancers deficient in dna double-strand break repair,” Journal of Clinical Oncology, Aug. 2008, vol. 26, No.…
[cited by applicant]
Audeh et al., “Novel treatment strategies in triple-negative breast cancer: specific role of poly(adenosine diphosphate-ribose) polymerase inhibition”, Pharmacogenomics and Personalized Medicine, 2014, vol. 7, pp. 307-3…
[cited by applicant]
Bamford et al., “The COSMIC (catalogue of somatic mutations in cancer) database and website”, British Journal of Cancer, 2004, vol. 91, pp. 355-358.
[cited by applicant]
Beder et al.: “Genome-wide analyses on loss of heterozygosity in head and neck squamous cell carcinomas”, Laboratory Investigation, 2003, vol. 83, No. 1, pp. 99-105.
[cited by applicant]
Bell et al., “Integrated genomic analyses of ovarian carcinoma,” Nature, Jun. 2011, vol. 474, pp. 609-615.
[cited by applicant]
Bengtsson et al., “A single-array preprocessing method for estimating full-resolution raw copy numbers from all Affymetrix genotyping arrays including GenomeWideSNP 5 & 6”, Bioinformatics, 2009, vol. 25, pp. 2149-2156.
[cited by applicant]
Bengtsson et al., “TumorBoost: Normalization of allele-specific tumor copy numbers from a single pair of tumor-normal genotyping microarrays”, BMC Bioinformatics. 2010, vol. 11, pp. 245-262.
[cited by applicant]
Bernardini et al., “The use of cytogenetics in understanding ovarian cancer”, Biomedicine and Pharmacotherapy, 2004, vol. 58, pp. 17-23.
[cited by applicant]
Beroukhim et al., “Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma”, Proc. Natl. Acad. Sci. U.S.A., 2007, vol. 104, No. 50, pp. 20007-20012.
[cited by applicant]
Beroukhim et al., “Inferring loss-of-heterozygosity from unpaired tumors using high-density oligonucleotide snp arrays”, Bioinformatics, vol. 19, No. 5, Jan. 2006, p. 2397.
[cited by applicant]
Birkbak et al., “Abstract 4823: Copy number gain and increased expression of BLM and FANCI is associated with sensitivity to genotoxic chemotherapy in triple negative breast and serous ovarian cancer”, Cancer Res., Apr.…
[cited by applicant]
Birkbak et al., “Amount of allelic imbalance predicts response to cisplatin in breast and Ovarian cancer”, Annals of Oncology, 2010, vol. 21.
[cited by applicant]
Birkbak et al., “Paradoxical relationship between chromosomal instability and survival outcome in cancer”, Cancer Res, May 2011, vol. 71, No. 10, pp. 3447-3452.
[cited by applicant]
Birkbak et al., “Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents”; Cancer Discov., 2012 vol. 2, No. 4, pp. 366-375.
[cited by applicant]
Bouwman et al., “53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers”, Nature Structural & Molecular Biology, Jun. 2010, vol. 17, No. 6, pp. 688-696.
[cited by applicant]
Bryant et al., “Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase”, Nature, 2005, vol. 434, No. 7035, pp. 913-917.
[cited by applicant]
Buch et al., “Prediction of recurrence of nonfunctioning pituitary tumours by loss of heterozygosity analysis”, Clinical Endocrinology, 2004, vol. 61, pp. 19-22.
[cited by applicant]
Bunting et al., “53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks”, Cell, 2010, vol. 141, No. 2, pp. 243-254.
[cited by applicant]
Burger et al. “Drug transporters of platinum-based anticancer agents and their clinical significance”, Drug Resistance Updates, 2011, vol. 14, pp. 22-34.
[cited by applicant]
Byrski et al., “Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients”, Breast Cancer Res Treat, 2009, vol. 115, pp. 359-363.
[cited by applicant]
Calvert et al., “245 Invited PARP inhibitors in cancer treatment”, European Journal of Cancer. Supplement, Pergamon, Oxford, GB, 2008, vol. 6, No. 12, p. 80.
[cited by applicant]
Campbell et al., “A genetic variant that disrupts MET transcription is associated with autism”, PNAS, Nov. 2006, vol. 103, pp. 16834-16839.
[cited by applicant]
Carr et al., “High-resolution analysis of allelic imbalance in neuroblastoma cell lines by single nucleotide polymorphism arrays”, Cancer Genetics and Cytogenetics, 2007, vol. 172, pp. 127-138.
[cited by applicant]
Cass et al., “Improved Survival in Women with BRCA-Associated Ovarian Carcinoma”, Cancer, May 2003, vol. 97, No. 9, pp. 2187-2195.
[cited by applicant]
Cerbinskaite et al., “Defective homologous recombination in human cancers”, Cancer Treat Rev; 2012; Epub 2011; vol. 38, No. 2, pp. 89-100.
[cited by applicant]
Cha et al., “ATR homolog mecl promotes fork progression, thus averting breaks in replication slow zones”, Science, Jul. 2002, vol. 297, pp. 602-606.
[cited by applicant]
Chang et al., “Assessment of plasma DNA levels, allelic imbalance, and CA 125 as diagnostic tests for cancer”, Journal of the National Cancer Institute, 2002, vol. 94, No. 22, pp. 1697-1703.
[cited by applicant]
Cheung et al., “Clinicopathologic significance of loss of heterozygosity on chromosome 1 in cervical cancer”, Gynecologic Oncology, Academic Press, London, GB, 2005, vol. 96, No. 2, pp. 510-515.
[cited by applicant]
Choi et al., “Genetic Classification of Colorectal Cancer Based on Chromosomal Loss and Microsatellite Instability Predicts Survival”, Clinical Cancer Research, Jul. 2002, vol. 8, pp. 2311-2322.
[cited by applicant]
Dann et al., “BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer”, Gynecol Oncol, 2012, vol. 125, No. 3, pp. 677-682.
[cited by applicant]
De Preter et al., “Application of laser capture microdissection in genetic analysis of neuroblastoma and neuroblastoma precursor cells”, Cancer Letters, 2003, vol. 197, pp. 53-61.
[cited by applicant]
De Soto et al., “The Inhibition and Treatment of Breast Cancer with Poly (ADP-ribose) Polymerase (PARP-1) Inhibitors”, Int. J. Biol. Sci., 2006, pp. 179-185.
[cited by applicant]
Duncavage et al., “Hybrid Capture and Next-Generation Sequencing Identify Viral Integration Sites From Formalin-Fixed, Paraffin-Embedded Tissue”, The Journal of Molecular Diagnostics, 2011, vol. 13, No. 3, pp. 325-333.
[cited by applicant]
Edwards et al., “Resistance to therapy caused by intragenic deletion in BRCA2”, Nature, 2008, vol. 451, No. 7182, pp. 1111-1115.
[cited by applicant]
Etemadmoghadam et al., “Integrated genome-wide dna copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas”, Clin Cancer Res, 2009, vol. 15, pp. 1417-1427.
[cited by applicant]
Fang et al., “Genomic differences between estrogen receptor (ER)-positive and er-negative human breast carcinoma identified by single nucleotide polymorphism array comparative genome hybridization analysis”, Cancer, May…
[cited by applicant]
Farmer et al, “Targeting DNA repair defect in BRCA mutant cells as a therapeutic strategy”, Nature; 2005; vol. 434, No. 7035, pp. 917-921.
[cited by applicant]
Feltmate et al., “Whole-genome allelotyping identified distinct loss-of-heterozygosity patterns in mucinous ovarian and appendiceal carcinomas”, Clinical Cancer Research, 2005, vol. 11, No. 21, pp. 7651-7657.
[cited by applicant]
Ferreira et al., “Array CGH and gene-expression profiling reveals distinct genomic instability patterns associated with DNA repair and cell-cycle checkpoint pathways in Ewing's sarcoma”, Oncogene, 2008, vol. 27, No. 14,…
[cited by applicant]
Filopanti et al., “Loss of heterozygosity at the SS receptor type 5 locus in human GH- and TSH-secreting pituitary adenomas”, J. Endocrinol. Invest., 2004, vol. 27, No. 10, pp. 937-942.
[cited by applicant]
Fontanillas et al., “Key considerations for measuring allelic expression on a genomic scale using high-throughput sequencing”, Molecular Ecology, 2010, vol. 19, No. 1, pp. 212-227.
[cited by applicant]
Franko et al., “Loss of heterozygosity predicts poor survival after resection of pancreatic adenocarcinoma,” J_ 3astrointesl. Surg., Oct. 2008, vol. 12, No. 10, pp. 1664-1723.
[cited by applicant]
Friedenson, “BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian”, MedGenMed; 2005; vol. 7(2), No. 60, 25 pages.
[cited by applicant]
Gelmon et al., “Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study”, Lancet Oncol,…
[cited by applicant]
Goransson et al., “Quantification of normal cell fraction and copy number neutral LOH in clinical lung cancer samples using SNP array data”, PLOS ONE, Jun. 26, 2009, vol. 4, No. 6, p. e6057.
[cited by applicant]
Gorringe et al., “Are there any more ovarian tumor suppressor genes? A new perspective using ultra high-resolution copy number and loss of heterozygosity analysis”, Genes Chromosomes & Cancer, John Wiley & Sons, NC, US,…
[cited by applicant]
Graziani et al., “PARP-1 inhibition to treat cancer, ischemia, inflammation”, Pharmacological Research, Academic Dress, London, GB, Jul. 1, 2005, vol. 52, No. 1, pp. 1-4.
[cited by applicant]
Gudmundsdottir et al., “The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability”, Oncogene, 2006, vol. 25, pp. 5864-5874.
[cited by applicant]
Gunnarsson et al. “Large but not small copy-number alterations correlate to high-risk genomic aberrations and survival n chronic lymphocytic lukemia: a high-resolution genomic screening of newly diagnosed patients”, Luk…
[cited by applicant]
Haluska et al., “HomologJus recombination deficiency (HRD) score and niraparib efficacy in high grade ovarian cancer”, European Journal of Cancer, 2014, vol. 50 Supplement, pp. 72-73.
[cited by applicant]
Hampton et al., “Simultaneous assessment of loss of heterozygosity at multiple microsatellite loci using semi-automated fluorescence-based detection: subregional mapping of chromosome 4 in cervical carcinoma”, PNAS, Jun…
[cited by applicant]
Hansen et al., “Clinical significance of homologous recombination deficiency score testing in endometrial cancer patients”, 2016, ASCO presentation.
[cited by applicant]
Hastings et al., “A Microhomology-Mediated Break-Induced Replication Model for the Origin of Human Copy Number Variation”, PLoS Genetics, Jan. 2009, vol. 5, No. 1, pp. 1-9, el000327.
[cited by applicant]
Hastings et al., “Mechanisms of change in gene copy number”, Nat Rev Genet, Aug. 2009, vol. 10, No. 8, pp. 551-564.
[cited by applicant]
Heap et al., “Genome-wide analysis of allelic expression imbalance in human primary cells by high-throughput transcriptome resequencing”, Human Molecular Genetics, Jan. 2010, vol. 19, No. 1, pp. 122-134.
[cited by applicant]
Heinsohn et al., “Determination of the prognostic value of loss of heterzygosity at the retinoblastoma gene in osteosarcoma”, Int. J. Oncol., May 2007, vol. 30, No. 5, pp. 1205-1214.
[cited by applicant]
Heiser et al., “Subtype and pathway specific responses to anticancer compounds in breast cancer”, PNAS, Feb. 2012, vol. 109, No. 8, pp. 2724-2729.
[cited by applicant]
Hendricks et al., Recombomice: The past, present, and future of recombination-detection in mice, DNA Repair, Oct. 5, 2004, vol. 3, No. 10, pp. 1255-1261.
[cited by applicant]
Hennessy et al., “Somatic mutations in BRCA 1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer”, J Clin Oncol., 2010, vol. 28, No. 22, pp. 3570-35…
[cited by applicant]
Holstege et al, “BRCA 1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP53 mutations”, BMC Cancer, 2010, vol. 10, No. 654, 15 pages.
[cited by applicant]
Horiuchi et al., “Epigenetic Changes during Ovarian Cancer Development and Progression—BRCAI Mehylation and SI00A4 Hypomethylation”, Acta Obstetrica et Gynaecologica Japonica, 2008, vol. 60, No. 11, pp. 1844-1854.
[cited by applicant]
Iafrate et al., “Detection of large-scale variation in the human genome”, Nature Genetics, Sep. 2004, vol. 36, No. 9, pp. 949-951.
[cited by applicant]
Isakoff et al., “TBCRC009: A multicenter phase II clinical trial of platinum monotherapy with biomarker assessment n metastatic triple-negative breast cancer”, J Clin Oncol, 2015, pp. 1-8.
[cited by applicant]
Jacobs et al., “Genome-Wide, High-Resolution Detection of Copy Number, Loss of Heterozygosity, and Genotypes from Formalin-Fixed, Paraffin-Embedded Tumor Tissue Using Microarrays”, Cancer Research, 2007, vol. 67, No. 6,…
[cited by applicant]
Janne et al. “High-resolution single-nucleotide polymorphism array and clustering analysis of loss of heterozygosity in human lung cancer cell lines”, Oncogene, Mar. 29, 2004, vol. 23, No. 15, pp. 2716-2726.
[cited by applicant]
Johannsdottir et al., “Chromosome 5 imbalance mapping in breast tumors from BRCA 1 and BRCA2 mutation carriers and sporadic breast tumors”, International Journal Of Cancer, John Wiley & Sons, Inc., US, vol. 119, No. 5, …
[cited by applicant]
Johansson et al., “Abstract 4833: A genomic portrait of tumor progression using next-generation sequencing”, Cancer Res., Apr. 15, 2011, vol. 71, p. 4833.
[cited by applicant]
Johansson et al., “Targeted resequencing of candidate genes using selector probes,” Nucleic Acids Research, 2011, vol. 39, pp. 1-13.
[cited by applicant]
Joosse et al., “Prediction of BRCA1-association in hereditary non-BRCAI/2 breast carcinomas with array-CGH”, Breast Cancer Res Treat, 2009, vol. 116, pp. 479-489.
[cited by applicant]
Juul et al., “A genomic profile derived summary measure of chromosomal breakpoints predicts response to treatment with the DNA-damaging agent cisplatin”, Cancer Research, 2009, vol. 69, No. 24, pp. 509S-51OS.
[cited by applicant]
Juul et al., “Amount of allelic imbalance predicts response to cisplatin in breast and ovarian cancer”, Annals of Oncology, 2010, vol. 21, 33 pages.
[cited by applicant]
Kaklamani et al., “Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579)”, Breast Cancer Res Treat, 2015, vol. 151, pp. 629-638.
[cited by applicant]
Kalb et al., “Fanconi anemia: causes and consequences of genetic instability”, Genome Dyn. Basel, Karger, 2006, vol. 1, pp. 218-242.
[cited by applicant]
Kamat et al., “Chemotherapy induced microsatellite instability and loss of heterozygosity in chromosomes 2, 5, 10, and 17 in solid tumor patients”, Cancer Cell International, 2014, vol. 14, pp. 118.
[cited by applicant]
Kerangueven et al., “Genome-wide search for loss of heterozygosity shows extensive genetic diversity of human breast carcinomas”, Cancer Research, 1997, vol. 57, No. 24, pp. 5469-5475.
[cited by applicant]
Kiialainen et al, “Performance of Microarray and Liquid Based Capture Methods for Target Enrichment for Massively Parallel Sequencing and SNP Discovery”, PLoS ONE, Feb. 2011, 6:e16486.
[cited by applicant]
Ko et al., “Frequent loss of heterozygosity on multiple chromosomes in Chinese esophageal squamous cell carcinomas”, Cancer Letters, 2001, vol. 170, No. 2, pp. 131-138.
[cited by applicant]
Kolomietz et al., “The role of alu repeat clusters as mediators of recurrent chromosomal aberrations in tumors”, Genes, Chromosomes & Cancer, 2002, vol. 35, pp. 97-112.
[cited by applicant]
Kudoh et al., “Gains of 1q21-q22 and 13ql2-ql4 are potential indicators for resistance to cisplatin-based chemotherapy in ovarian cancer patients”, Clinical Cancer Research, Sep. 1999, vol. 5, pp. 2526-2531.
[cited by applicant]
Kujawski et al., “Genomic complexity identifies patients with aggressive chronic lymphocytic leukemia”, Blood, Sep. 2008, vol. 112, No. 5, pp. 1993-2003.
[cited by applicant]
Lakhani et al., “Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype”, Clin Cancer Res, Jul. 2005, vol. 11, No. 14, pp. 5175-5180.
[cited by applicant]
Ledermann et al., “Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer”, N Engl J Med, 2012, vol. 366, pp. 1382-1392.
[cited by applicant]
Lemeta et al., “Loss of Heterozygosity at 6q is Frequent and Concurrent with 3p Loss in Sporadic and Familial Capillary Hemangioblastomas”, J. Neuropathol. Exp. Neural., Oct. 2004, vol. 63, No. 10, pp. 1072-1079.
[cited by applicant]
Leunen et al., “Recurrent copy number alterations in BRCA1-mutated ovarian tumors alter biological pathways”, Human Mutation, 2009, vol. 30, No. 12, pp. 1693-1702.
[cited by applicant]
Lheureux et al., “Long-term responders of olaparib maintenance in high-grade serous ovarian cancer: Clinical and molecular characterization”, Clin Cancer Res., 2017, vol. 23, No. 15, pp. 4086-4094.
[cited by applicant]
Li et al., “Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer”, Nature Medicine, Feb. 2010, vol. 16, No. 2, pp. 214-219.
[cited by applicant]
Li et al., “Jetset: selecting the optimal microarray probe set to represent a gene”, Bioinformatics, 2011, vol. 12: p. 474.
[cited by applicant]
Li et al., “Major copy proportion analysis of tumor samples using SNP arrays”, BMC Bioinformatics, 2008, vol. 9, No. 204, pp. 1-16.
[cited by applicant]
Lieberfarb et al., “Genome-wide loss of heterozygosity analysis from laser capture microdissected prostate cancer using single nucleotide polymorphic allele (snp) arrays and a novel bioinformatics platform dchipSNP”, Ca…
[cited by applicant]
Lin et al. “Integrated analysis of copy number alterations and loss of heterozygosity in human pancreatic cancer using high-resolution, single nucleotide polymorphism array”, Oncology, 2008, vol. 75, No. 1-2, pp. 102-11…
[cited by applicant]
Loveday et al., “Germline mutations in RAD51D confer susceptibility to ovarian cancer”, Nat Genet., 2011, vol. 43, No. 9, pp. 879-882.
[cited by applicant]
Luo et al., “Cancer predisposition caused by elevated mototic recombination in Bloom mice”, Nature Genetics, Dec. 2000, vol. 26, pp. 424-429.
[cited by applicant]
Maeck et al. “Genetics instability in myelodysplastic syndrome: Detection of microsatellite instability and loss of heterozygosity in bone marrow samples with karyotype alterations” British Journal of Haematology, Jun. …
[cited by applicant]
Marsit et al., “Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival”, Oncogene; 2004, vol. 23, No. 4, pp. 1000-1004.
[cited by applicant]
Mateo et al., “Appraising iniparib, the PARP inhibitor that never was—what must we learn?,” Nature, Dec. 2013, vol. 10, pp. 688-696.
[cited by applicant]
Matsumoto et al., “Allelic imbalance at 1P36 may predict prognosis of chemoradiation therapy for bladder reservation in patients with invasive bladder cancer”, British Journal of Cancer, 2004, vol. 91, No. 6, pp. 1025-1…
[cited by applicant]
Mcvean, “What drives recombination hotspots to repeat DNA in humans?”, Phil. Trans. R. Soc. B, 2010, vol. 365, pp. 1213-1218.
[cited by applicant]
Meadows et al. “Genome-wide analysis of loss of heterozygosity and copy number amplification in uterine leiomyomas using the 100K single nucleotide polymorphism array”, Experimental and Molecular Pathology, Apr. 2011, v…
[cited by applicant]
Medri et al., “Prognostic relevance of mitotic activity in patients with node-negative breast cancer”, Modern Pathology, 2003, vol. 16, No. 11, pp. 1067-1075.
[cited by applicant]
Mei et al., “Genome-wide detection of allelic imbalance using human SNPs and high-density DNA arrays”, Genome Research, 2000, vol. 10, pp. 1126-1137.
[cited by applicant]
Meindl et al; Germline mutations in breast and ovarian cancer pedigrees establish RAD51Casa human cancer susceptibility gene; Nat Genet; 2010; vol. 42, No. 5, pp. 410-414.
[cited by applicant]
Mendes-Pereira et al., “Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors”, EMBO Mol Med, 2009, vol. 1, Nos. 6-7, pp. 315-322.
[cited by applicant]
Mills et al., “Homologous Recombination Deficiency (HRD) Score Shows Superior Association with Outcome Compared to its Individual Score Components (LOH, TAI, and LST Scores) in Platinum Treated Serous Ovarian Cancer”, A…
[cited by applicant]
Mukhopadhyay et al., “Clinicopathological Features of Homologous Recombination-Deficient Epithelial Ovarian Cancers: Sensitivity to PARP Inhibitors, Platinum, and Survival,” Cancer Research, 2012, pp. 5675-5682.
[cited by applicant]
Murayama-Hosokawa et al., “Genome-wide single-nucleotide polymorphism arrays in endometrial carcinomas associate extensive chromosomal instability with poor prognosis and unveil frequent chromosomal imbalances involved …
[cited by applicant]
Nannya et al., “A robust algorithm for copy number detection using high-density oligonucleotide single nucleotide polymorphism genotyping arrays”, Cancer Res., 2005, vol. 65, No. 14, pp. 6071-6079.
[cited by applicant]
Narayan et al; “Frequent promoter of methylation of CDH1, DAPK, RARB, and HIC1 genes in carcinoma of cervix uteri: its relationship to clinical outcome”, Mol Cancer, 2003, vol. 2, No. 24, 12 pages.
[cited by applicant]
Norquist et al., “Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas”, J Clin Oncol, 2011, vol. 29, No. 22, pp. 3008-3015.
[cited by applicant]
Novak et al., “A high-resolution allelotype of B-cell chronic lymphocytic leukemia (B-CLL)”, Blood, Sep. 2002, vol. 100, No. 5, pp. 1787-1794.
[cited by applicant]
O'Brien et al., “Converting cancer mutations into therapeutic opportunities,” EMBO Mol. Med., 2009, vol. 1, pp. 297-299.
[cited by applicant]
O'Shaugnessy et al., “Iniparib plus chemotherapy in metastatic triple-negative breast cancer”, N Engl J Med., 2011, vol. 364, No. 3, pp. 205-214.
[cited by applicant]
Ogston et al., “A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survial”, The Breast, 2003, vol. 12, pp. 320-327.
[cited by applicant]
Osborne et al., “A genome-wide map showing common regions of loss of heterozygosity/allelic imbalance in breast cancer”, Cancer Res, 2000, vol. 60, pp. 3706-3712.
[cited by applicant]
Ott et al., “Chromosomal instability rather than p53 mutation is associated: with response to neoadjuvant cisplatin-based chemotherapy in gastric carcinoma”, Clinical Cancer Research, The American Association for Cancer…
[cited by applicant]
Patel et al., “Failure of Iniparib to Inhibit Poly(ADP-Ribose) Polymerase in Vitro”, Clin Cancer Res, Mar. 2012, pp. 1655-1662.
[cited by applicant]
Patocs et al., “Breast-cancer stromal cells with TP53 mutations and nodal metastases”, N. Engl. J. Med., 2007, vol. 357, pp. 2543-2551.
[cited by applicant]
Peng et al., “Genome-wide transcriptome profiling of homologous recombination DNA repair”, Nature Communications 2014, pp. 1-11.
[cited by applicant]
Penning et al., “Discovery and SAR of 2-(1-propylpiperidin-4-y1)-1H-benzimidazole-4-carboxamide: A potent inhibitor of poly(ADP-ribose) polymerase (PARP) for the treatment of cancer”, Bioorganic & Medicinal Chemistry, P…
[cited by applicant]
Pfeifer et al., “Genome-wide analysis of DNA copy number changes and LOH in CLL using high-density SNP arrays”, Blood, Oct. 5, 2006, vol. 109, No. 3, pp. 1202-1210.
[cited by applicant]
Popova et al., “Genome Alteration Print (GAP): a tool to visualize and mine complex cancer genomic profiles obtained by SNP arrays”, Genome Biology, Biomed Central Ltd., London, GB, Nov. 11, 2009, vol. 10, No. 11, p. R1…
[cited by applicant]
Popva et al., “Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCAI/2 inactivation”, Cancer Research, Nov. 1, 2012, vol. 72, No. 21, pp. 5454-5462.
[cited by applicant]
Puliti et al., “Low-copy repeats on chromosome 22q11.2 show replication timing switches, DNA flexibility peaks and stress inducible asynchrony, sharing instability features with fragile sites”, Mutat Res., 2010, vol. 68…
[cited by applicant]
Rakha et al., “Basal-Like Breast Cancer: A Critical Review”, Journal of Clinical Oncology, May 2008, vol. 26, No. 15, pp. 2568-2581.
[cited by applicant]
Ramirez et al., “Loss of 1p, 19q, and 10q heterozygosity prospectively predicts prognosis of oligodendroglial tumors—towards individualized tumor treatment?”, Neuro. Oncol., May 2010, vol. 12, No. 5, pp. 490-499.
[cited by applicant]
Richard et al., “Comparative Genomics and Molecular Dynamics of DNA Repeats in Eukaryotes”, Microbiology and Molecular Biology Reviews, Dec. 2008, pp. 686-727.
[cited by applicant]
Richardson et al., “X chromosomal abnormalities in basal-like human breast cancer”, Cancer Cell, Feb. 2006, vol. 9, pp. 121-132.
[cited by applicant]
Roscillli et al., Annual Meeting of the American Association for Cancer Research, Apr. 17-21, 2010, No. 685, 5 pages.
[cited by applicant]
Ross et al., “Comprehensive next-generation sequencing for clinically actionable mutations from formalin-fixed cancer tissues”, Journal of Clinical Oncology, 2011, 15 Supp: 1-3, abstract.
[cited by applicant]
Ryan et al, “Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): Safety and efficacy”, 2009 ASCO Annual Meeting, http://meetinglibrary.asco.org/content/34135-65, (2009).
[cited by applicant]
Sakai et al., “Functional resoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma”, Cancer Res, 2009, vol. 69, No. 16, pp. 6381-6386.
[cited by applicant]
Sakai et al., “Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers”, Nature, 2008, vol. 451, No. 7182, pp. 1116-1120.
[cited by applicant]
Samouelian et al., “Chemosensitivity and radiosensitivity profiles of four new human epithelial ovarian cancer cell lines exhibiting genetic alterations in BRCA2 TGFB-RII KRAS2 TP53 and/or CDNK2A”, Cancer Chemother Phar…
[cited by applicant]
Sandhu et al., “The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial”, Lancet Oncology, Aug. 2013, vol. 14, No. 9, pp.…
[cited by applicant]
Sang-Wook et al. “Genetic classification of colorectal cancer based on chromosomal loss and microsatellite instability predicts survival”, Clinical Cancer Research, The American Association For Cancer Research, US, Jul.…
[cited by applicant]
Santana-Davila et al., “Treatment options for patients with triple-negative breast cancer”, Journal of Hematology & Oncology, Oct. 2010, vol. 3, No. 42, 11 pages.
[cited by applicant]
Schouten et al., “Challengers in the use of DNA repair deficiency as a biomarker in breast cancer”, Journal of Clinical Oncology, 2015, vol. 33, No. 17, pp. 1867-1869.
[cited by applicant]
Schwartz et al., “Homologous recombination and nonhomologous end-joining repair pathways regulate fragile site stability”, Genes & Development, 2005, 19: 2715-2726.
[cited by applicant]
Schweiger et al., “Genome-Wide Massively Parallel Sequencing of Formaldehyde Fixed-Paraffin Embedded (FFPE) Tumor Tissues for Copy-Number- and Mutation-Analysis”, PLoS ONE, 2009, 4:e5548.
[cited by applicant]
Sebat et al., “Large-Scale Copy Number Polymorphism in the Human Genome”, Science, Jul. 2004, 305:525-528.
[cited by applicant]
Shanda et al., “Homologous Recombination Deficiency (HRD) in Patients with Pancreatic Cancer and Response to Chemotherapy”, 2017, ASCO presentation.
[cited by applicant]
Silva et al., “Loss of heterozygosity in BRCA1 and BRCA2 markers and high-grade malignancy in breast cancer”, Breast Cancer Res. Treat, 1999, vol. 53, Mo. 1, pp. 9-17.
[cited by applicant]
Silver et al., “Efficacy of neoadjuvant cisplatin in triple-negative breast cancer”, J. Clin. Oncol., 2010, vol. 28, pp. 1145-1153.
[cited by applicant]
Silver et al., “Further evidence for BRCA1 communication with the inactive X chromosome”, Cell, Mar. 2007, vol. 128, No. 5, pp. 991-1002.
[cited by applicant]
Smid et al., “Patterns and incidence of chromosomal instability and their prognostic relevance in breast cancer subtypes”, Breast Cancer Research and Treatment, Kluwer Academic Publishers, BO, Jul. 15, 2010, vol. 128, N…
[cited by applicant]
Sorlie et al., “Repeated observation of breast tumor subtypes in independent gene expression data sets”, PNAS, Jul. 2003, vol. 100, No. 14, pp. 8418-8423.
[cited by applicant]
Soule et al., “Isolation and Characterization of a Spontaneously Immortalized Human Breast Epithelial Cell Line, MCF-10”, Cancer Research, Sep. 15, 1990, vol. 50, pp. 6075-6086.
[cited by applicant]
Stankiewicz et al., “Genome architectre catalyzes nonrecurrent chromosomal rearrangements”, Am. J. Hum. Genet., 2003, vol. 72, pp. 1101-1116.
[cited by applicant]
Stefansson et al., “Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes”, Breast Cancer Res; 2009; vol. 11, No. 4, R47, 14 pages.
[cited by applicant]
Stronach et al., “Biomarker assessment of hr deficiency, tumor BRCA1/2 mutations, and CCNE1 copy number in ovarian cancer: associations with clinical outcome following platinum monotherapy”, Mol Cancer Res., Jul. 2018, …
[cited by applicant]
Swisher et al., “Secondary BRCA1 mutations in BRCAI-mutated ovarian carcinomas with platinum resistance”, Cancer Res., Apr. 2008, vol. 68, No. 8, pp. 2581-2586.
[cited by applicant]
Tai et al., “High-throughput loss-of-heterozygosity study of chromosome 3p in lung cancer using single-nucleotide polymorphism markers”, Cancer Research, Apr. 2006, vol. 66, No. 8, pp. 4133-4138.
[cited by applicant]
Takahashi et al., “Clonal and parallel evolution of primary lung cancers and their metastases revealed by molecular dissection of cancer cells”, Clinical Cancer Research, 2007, vol. 13, No. 1, pp. 111-120.
[cited by applicant]
Tan et al; ‘BRCAness’ syndrome in ovarian cancer: a case-control study describing the clinical features and outcome Jf patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations; J Clin Oncol., 20…
[cited by applicant]
Tassone et al., “BRCAI expression modulates chemosensitivity of BRCAI-defective HCCI937 human breast cancer cells”, British Journal of Cancer, 2003, vol. 88, pp. 1285-1291.
[cited by applicant]
Teh et al., “Genomewide single nucleotide polymorphism microarray mapping in basal cell carcinomas unveils uniparental disomy as a key somatic event”, Cancer Research, Oct. 2005, vol. 65, No. 19, pp. 8597-8603.
[cited by applicant]
Telli et al., “Abstract PD09-04: Homologous Recombination Deficiency (HRD) score predicts pathologic response following neoadjuvant platinum-based therapy in triple-negative and BRCA1/2 mutation-associated breast cancer…
[cited by applicant]
Telli et al., “Phase II study of gemcitabine, carboplatin, and Iniparib as neoadjuvan therapy for triple-negative and BRCA1/2 mutation-associated breast cancer with assessment of a tumor-based measure of genomic instabi…
[cited by applicant]
The Cancer Genome Atlas Research Network, “Integrated genomic analyses of ovarian carcinoma”, Nature, 2011, vol. 474, No. 7353, pp. 609-615.
[cited by applicant]
Timms et al., “Abstract P6-05-1 0: Association between BRCA 1 /2 status and DNA-based assays for homologous recombination deficiency in breast cancer”, Dec. 2013 , Abstracts: Thirty-Sixth Annual CTRC-AACR San Antonio, T…
[cited by applicant]
Timms et al., “Association of BRCA 712 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes,” Breast Cancer Research, 2014, vol. 16, pp. 1-9.
[cited by applicant]
Timms et al., “DNA repair deficiences in ovarian cancer: Genomic analysis of high grade serous ovarian tumors from the NOVA Study”, 2015, ESMO presentation, 1 page.
[cited by applicant]
Timms et al., “The Molecular landscape of genome instability in prostate cancer”, 2016, ESMO presentation, 1 page.
[cited by applicant]
Tommasi et al., “655Val and 1170Pro ERBB2 SNPs in familial breast cancer risk and BRCA1 alterations” Cellular Oncology, 2007, vol. 29, pp. 241-248/.
[cited by applicant]
Tseng et al., “Genomewide loss of heterozygosity and its clinical associations in non-small cell lung cancer”, Int Cancer, Nov. 2005, vol. 117, No. 2, pp. 241-247.
[cited by applicant]
Tuna et al., “Association between Acquired Uniparental Diomy and Homozygous Mutations and HER2/ER/PR Status in Breast Cancer”, PLoS One , 2010, vol. 5, No. 11, e15094.
[cited by applicant]
Turner et al., “BRCA1 dysfunction in sporadic basal-like breast cancer,” Oncogene, 2007, vol. 26, pp. 2126-2132.
[cited by applicant]
Valeri et al., “High frequency of allelic losses in high-grade prostate cancer is associated with biochemical progression after radical prostatctomy”, Urologic Oncology, Elsevier, New York, NY, US, Mar. 2005, vol. 23, N…
[cited by applicant]
Van Loo et al., “Allele-specific copy number analysis of tumors”, PNAS, 2010, vol. 107, No. 39, pp. 16910-16915.
[cited by applicant]
Varley et al., “Nested Patch PCR enables highly multiplexed mutation discovery in candidate genes”, Genome Research, 2008, vol. 18, pp. 1844-1850.
[cited by applicant]
Volchenboum et al. “Comparison of primary neuroblastoma tumors and derivative early-passage cell lines using genome-wide single nucleotide polymorphism array analysis”, Cancer Research, May 2009, vol. 69, No. 10, pp. 41…
[cited by applicant]
Vollenbergh et al. “Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers”, CMLS Cellular and Molecular Life Science, Birkhauser-Verlag, BA, Sep. 2011, vol. 69, No. 2, pp. 22…
[cited by applicant]
Vrieling, “Mitotic maneuvers in the light”, Nature Genetics, Jun. 2001, vol. 28, pp. 101-102.
[cited by applicant]
Walsh et al., “Genome-wide loss of heterozygosity and uniparental disomy in BRCA1/2-associated ovarian carcinomas”, Clin Cancer Res, Dec. 2008, vol. 14, No. 23, p. 7645-7651.
[cited by applicant]
Wang et al., “Analysis of molecular inversion probe performance for allele copy number determination”, Genome Biol, 2007, vol. 8, No. 11, R246.
[cited by applicant]
Wang et al., “Loss of heterozygosity and its correlation with expression profiles in subclasses of invasive breast cancers”, Cancer Res, Jan. 2004, vol. 64, No. 1, pp. 64-71.
[cited by applicant]
Wilcox et al., “High-resolution methylation analysis of the BRCA1 promoter in ovarian tumors”, Cancer Genet Cytogenet, 2005, vol. 159, No. 2, pp. 114-122.
[cited by applicant]
Wilcoxen et al., “Homologous recombination deficiency (HRD) score enriches for niraparib sensitive high grade ovarian tumors,” Supplemental Abstract, 2015, 1 page.
[cited by applicant]
Wilcoxen et al., “Use of homologous recombination deficiency (HRD) score to enrich for niraparib sensitive high grade ovarian tumors, ”J Clin Oncol, 2015, Supplemental Abstract: 5532, 2 pages.
[cited by applicant]
Xiao et al., “The XIST Noncoding RNA Functions Independently of BRCA1 in X Inactivation”, Cell, Mar. 2007, vol. 128, pp. 977-989.
[cited by applicant]
Xu et al., “Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 Exon 11 Isoform-deficient cells”, Molecular Cell, 1999, vol. 3, pp. 389-395.
[cited by applicant]
Yang et al., “Reconstitution of caspase 3 sensitizes MCF-7 breast cancer cells to doxorubicin- and etoposide-induced apoptosis”, Cancer Res, Jan. 2001, vol. 61, No. 1, pp. 348-354.
[cited by applicant]
Yaris et al., “Primary cerebral neuroblastoma: a case treated with adjuvant chemotherapy and radiotherapy”, The Turkish Journal of Pediatrics, 2004, vol. 46, pp. 182-185.
[cited by applicant]
Zhao et al., “Systematic detection of putative tumor suppressor genes through the combined use of exome and transcriptome sequencing”, Genome Biol., 2010, vol. 11: R114, pp. 1-14.
[cited by applicant]
Zuchner et al., “Linkage and association study of late-onset Alzheimer disease families linked to 9p21.3”, Ann Hum Genet, Nov. 2008, vol. 72, No. Pt 6, p. 725.
[cited by applicant]
Makishima et al., “Pathogenesis and Consequences of Uniparental Disomy in Cancer”, Clinical Cancer Research, vol. 17, No. 12, Jun. 15, 2011, pp. 3913-3923.
[cited by applicant]
Smida et al., “Genomic Alterations and Allelic Imbalances are Strong Prognostic Predictors in Osteosarcoma,” Clinical Cancer Research, vol. 16, No. 16, Aug. 15, 2020, pp. 4256-4267.
[cited by applicant]
Curulli, E.T. et al. Genome Biology 11:R57 (8 pages). May 2010. (Year: 2010).
[cited by applicant]
Nielsen, R. et al. Nature Reviews: Genetics 12:443-451. May 2011. (Year: 2011).
[cited by applicant]